05 February 2026
05 February 2026
Participants will each receive a single intravenous infusion of AFTX-201 at doses determined from preclinical studies.
The closing of this transaction is expected during the second half of 2026.
The one-year data covers 94 high surgical risk patients across all arms.
The trial is conducted at the Mays Cancer Center, part of the University of Texas at San Antonio’s Health Science Center.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
